According to a new market report published by Lucintel, the future of the HER2 (Human Epidermal Growth Factor Receptor 2) antibody market looks promising with opportunities in hospitals and medical centers. The global HER2 antibody market is expected to grow with a CAGR of 9% from 2020 to 2025. The major drivers for this market are increasing prevalence of HER2 positive, rising awareness of personalized medicines, and increasing geriatric population.
To download report brochure, please go to https://www.lucintel.com/her2-antibody-market.aspx and click "download brochure" tab from the menu
HER2 (Human Epidermal Growth Factor Receptor 2) is a gene that can play a role in the development of breast cancer. Trastuzumab is a monoclonal antibody that targets HER2. In this market, trastuzumab, lapatinib, ado-trastuzumab emtansine, pertuzumab, and everolimus are the major type of treatment drugs. Lucintel forecasts that trastuzumab will remain the largest treatment drug type segment over the forecast period due to increasing prevalence of cancer.
North America will remain the largest region over the forecast period due to developed healthcare infrastructure and increasing awareness of population regarding the treatment of HER2 breast cancer in the region.
Roche, Novartis, Abnova, Pfizer, InvivoGen, Biocon, Bio-Techne, Samsung Bioepis, and Celltrion are among the major suppliers in the global HER2 antibody market.
Lucintel, a leading global strategic consulting and market research firm, has analyzed growth opportunities in the global HER2 antibody market by type of treatment drug, application, sales channel, and region. Lucintel has prepared a comprehensive research report titled “Growth Opportunities in the Global HER2 Antibody Market 2020-2025: Trends, Forecast, and Opportunity Analysis.” This Lucintel report serves as a catalyst for growth strategy, as it provides comprehensive data and analysis on trends, key drivers, and directions. The study includes trends and forecast for the global HER2 antibody market by type of treatment drug, application, sales channel, and region as follows:
By Type of Treatment Drugs [Value ($ Million) shipment analysis for 2014 – 2025]:
Trastuzumab
Lapatinib
Ado-trastuzumab Emtansine
Pertuzumab
Everolimus
By Application [Value ($ Million) shipment analysis for 2014 – 2025]:
Hospitals
Medical Centers
By Distribution Channel [Value ($ Million) shipment analysis for 2014 – 2025]:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
United States
Canada
Mexico
United Kingdom
Germany
France
This 150-page research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or visit us at helpdesk@lucintel.com.
About Lucintel
Lucintel, the premier global Management Consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, Growth Consulting, M&A, and Due diligence services to executives and key decision makers in a variety of industries. For further information, visit www.lucintel.com.